Aptamer-based analysis of plasma proteome of growing tumors

Background

In most cases, detecting malignancies at an early-stage increases treatment options, minimizes the risk of metastases and dramatically improves long-term survival. Nevertheless, tumors are typically discovered at more advanced stages, either with onset of symptoms or as part of unrelated procedures. Non-invasive means of detecting tumors in systemic circulation has long held considerable appeal, but also enormous challenges. A major difficulty is related to the need to detect a small volume of a malignancy remotely, after massive dilution of tumor-associated analytes in the total circulating volume of blood. To date, such “liquid biopsies” have mainly focused on the identification of genetic material unique to transformed cells, typically derived from circulating tumor cells, or cell-free DNA. With proteins, the presence of a tumor is more often accompanied with changes in the levels of endogenous, unmutated proteins in circulation. In this context, knowing which proteins represent the earliest markers or tumor presence would be enormously useful. So what are the first tumor-associated proteins that can be detected in blood as the initial transformed cells establish residence in their tissues of origin?

Methods

To answer this question, we used aptamer-based SomaScan® assay to monitor the time course of changes in the plasma proteome of mice carrying transplanted human tumors.

Results

Our study shows that tumor cells representing human lung, ovarian, breast and colon cancer produce both unique and common sentinel proteomic signatures in plasma that could be used to identify both the early presence as well as the identity of tumors growing remotely.

Conclusions

  • Mouse models of human tumor growth reveal the emergence of early protein markers of tumor presence in plasma
  • Unique and common markers exist for lung, colon, ovarian and breast cancer cell lines
  • Tests based on multiple protein analytes reveal tumors at an early stage
  • Protein-based tests can enhance the performance of liquid biopsies

Authors

Shashi Gupta1
Matthew Westacott1
Deborah G. Ayers1
Daniel J. Schneider1
Anis Karimpour-Fard2
Lawrence E. Hunter2
Daniel W. Drolet1
Nebojsa Janjic1

1. SomaLogic Operating Co., Inc., Boulder, CO, USA
2. University of Colorado School of Medicine, Aurora, CO, USA


Share with colleagues

More posters

PosterPrognostic proteomic models for low event rates: A case study with myocardial infarction

We have developed and assessed a novel prognostic model development method combining two statistical techniques – survival analysis and subsampling – using existing machine learning tools in R.

Learn more

PosterProteomic Models to Predict Pre-Analytical Variation

In biomarker discovery, it is critical to assess any pre-analytical variation (PAV) in order to avoid artificial bias in the intended measurements. PAV may arise from both avoidable and unavoidable factors, resulting in misleading data and incorrect conclusions. Proteins, in particular, are vulnerable to variation in collection methods, storage temperatures, and processing protocols. It is vitally important to understand this PAV when analyzing samples using protein assays.

Learn more

PosterEfficient development of certified diagnostic laboratory developed tests using proteomic data

We demonstrate the utility of combining pipeline tools, statistical learning techniques, and a knowledge base of in-silico proteomic datasets into a reproducible workflow that allows for efficient development of LDT-certifiable tests using SomaScan® technology.

Learn more

Explore posters in our interactive viewer